Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026

Kintor Pharmaceutical (HKG: 9939) announced that it has entered into an exclusive product distribution agreement...

Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that it has received a USD 30 million upfront...

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Fineline Cube Aug 12, 2026

Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that the New Drug Application (NDA) for...

Company Medical Device PIC

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Fineline Cube Aug 12, 2026

The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.‘s (a genetic cancer testing service...

Company Deals Digital PIC

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026

Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of a Series...

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral...

Company Medical Device

Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism

Fineline Cube Aug 12, 2026

Shanghai Haohai Biological Technology Co. Ltd. (SHA: 688366) announced that its trifocal toric intraocular lens...

Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its self‑developed 9‑valent human...

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that it has entered into...

Company Deals PIC

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Fineline Cube Aug 12, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...

Company Deals PIC

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the...

Company Deals PIC

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026

IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...

Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026

Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to...

Company Deals PIC

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Fineline Cube Aug 12, 2026

CanSino Biologics (HKG: 6185) announced that it reached a cooperation intent with its Pakistani partner...

Company Deals

Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST‑4003 In Vivo CAR‑T Candidate in China

Fineline Cube Aug 12, 2026

Tempest Therapeutics, Inc. (NASDAQ: TPST) announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd....

Company Deals

Zhaoke Ophthalmology Signs Strategic MOU With Brazil’s Teuto at BIO 2026 – First Latin America Eye‑Care Market Entry

Fineline Cube Aug 12, 2026

Zhaoke Ophthalmology Limited (HKG: 6622) announced that it signed a strategic cooperation memorandum with Brazilian...

Company Deals PIC

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Fineline Cube Aug 11, 2026

GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate...

Company Deals PIC

Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform

Fineline Cube Aug 11, 2026

Hangzhou Eli Radiopharma Co., Ltd. and Shanghai Smartlogic Technology Ltd. officially signed a strategic cooperation...

Company Deals

Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System

Fineline Cube Aug 11, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and GemPharmatech Inc. (SHA: 688046) officially signed...

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Fineline Cube Aug 11, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced an out‑licensing agreement with Menarini for Bonfaglutide Injection...

Posts pagination

1 … 12 13 14 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.